Engaging European society at the forefront of cancer research and care: How discussions at the 5

Mission on Cancer cancer prevention cancer research policy

Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
06 2023
Historique:
revised: 26 03 2023
received: 17 03 2023
accepted: 17 03 2023
medline: 12 6 2023
pubmed: 21 3 2023
entrez: 20 3 2023
Statut: ppublish

Résumé

European cancer research stakeholders met in October 2022 in Heidelberg, Germany, at the 5

Identifiants

pubmed: 36938773
doi: 10.1002/1878-0261.13423
pmc: PMC10257409
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

925-945

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Références

JCO Clin Cancer Inform. 2022 Mar;6:e2100149
pubmed: 35483002
Mol Oncol. 2022 Sep;16(18):3220-3237
pubmed: 35503718
Mol Oncol. 2017 Dec;11(12):1661-1672
pubmed: 29024497
Mol Oncol. 2020 Aug;14(8):1589-1615
pubmed: 32749074
Eur J Cancer. 2020 Apr;129:41-49
pubmed: 32120274
Nature. 2019 Oct;574(7776):127-131
pubmed: 31570881
Lancet Oncol. 2023 Jan;24(1):5-6
pubmed: 36400099
Mol Oncol. 2019 Mar;13(3):549-557
pubmed: 30698321
Mol Oncol. 2019 Mar;13(3):497-501
pubmed: 30811864
Int J Cancer. 2022 Feb 15;150(4):580-593
pubmed: 34569617
Mol Oncol. 2021 Oct;15(10):2507-2543
pubmed: 34515408
Lancet Oncol. 2023 Jan;24(1):8-9
pubmed: 36400105
Diagnostics (Basel). 2021 Nov 15;11(11):
pubmed: 34829458
BMJ. 2022 Feb 2;376:o282
pubmed: 35115384
BMJ Open. 2020 Nov 17;10(11):e043828
pubmed: 33203640
Nat Cancer. 2022 Feb;3(2):251-261
pubmed: 35221333
Cancer Manag Res. 2022 Oct 31;14:3105-3118
pubmed: 36340999
Clin Pharmacol Ther. 2019 Apr;105(4):867-877
pubmed: 30636285
Ann Oncol. 2018 Sep 1;29(9):1895-1902
pubmed: 30137196
Mol Oncol. 2019 Mar;13(3):567-578
pubmed: 30582778
Cancer Causes Control. 2014 May;25(5):615-24
pubmed: 24658968
Diagnostics (Basel). 2022 Mar 30;12(4):
pubmed: 35453900
N Engl J Med. 2017 May 25;376(21):2006-2009
pubmed: 28538124
Mol Oncol. 2019 Mar;13(3):528-534
pubmed: 30667152
Lancet Oncol. 2018 Aug;19(8):1014-1015
pubmed: 30102210
Mol Oncol. 2021 Dec;15(12):3225-3241
pubmed: 34003576
Eur J Cancer. 2021 Nov;157:308-347
pubmed: 34560371
BMJ. 2022 Sep 21;378:o2197
pubmed: 36130783
Mol Oncol. 2018 Nov;12(11):1829-1837
pubmed: 30241109
Lancet Oncol. 2023 Jan;24(1):e11-e56
pubmed: 36400101
Lancet Oncol. 2023 Jan;24(1):6-8
pubmed: 36400103
Mol Oncol. 2009 Feb;3(1):5-8
pubmed: 19383361
Nat Genet. 2020 Apr;52(4):448-457
pubmed: 32246132
Front Pharmacol. 2021 Aug 10;12:699466
pubmed: 34456724
Ann Oncol. 2021 Jul;32(7):926-932
pubmed: 33862157

Auteurs

Michael Baumann (M)

German Cancer Research Center (DKFZ), Heidelberg, Germany.
European Academy of Cancer Sciences, Stockholm, Sweden.

Julio Celis (J)

European Academy of Cancer Sciences, Stockholm, Sweden.
Danish Cancer Society Research Center, Copenhagen, Denmark.

Ulrik Ringborg (U)

European Academy of Cancer Sciences, Stockholm, Sweden.
Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden.

Manuel Heitor (M)

European Academy of Cancer Sciences, Stockholm, Sweden.
Center for Innovation, Technology and Policy Research, IN+ @ IS Técnico, University of Lisbon, Portugal.

Anton Berns (A)

European Academy of Cancer Sciences, Stockholm, Sweden.
The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Tit Albreht (T)

National Institute of Public Health of Slovenia, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Slovenia.

Jeliazko Arabadjiev (J)

Clinic of Medical Oncology, University Hospital Acibadem City Clinic Tokuda, Sofia, Bulgaria.
Bulgarian Scientific Society of Immuno-oncology, and MoC Board, Sofia, Bulgaria.

Michael Boutros (M)

European Academy of Cancer Sciences, Stockholm, Sweden.
Division Signaling and Functional Genomics, German Cancer Research Center (DKFZ) and Heidelberg University, Germany.
DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany.

Mario Brandenburg (M)

Federal Ministry of Education and Research (BMBF), Berlin, Germany.

Helena Canhao (H)

Comprehensive Health Research Center (CHRC), NOVA Medical School, Universidade Nova de Lisboa, Portugal.

Fatima Carneiro (F)

European Academy of Cancer Sciences, Stockholm, Sweden.
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (Ipatimup), Portugal.
Instituto de Investigação e Inovação em Saúde (i3S), Faculdade de Medicina da Universidade do Porto (FMUP), Portugal.
Centro Hospitalar Universitário de São João (CHUSJ), Porto, Portugal.

Christine Chomienne (C)

Université de Paris, France.

Francesco De Lorenzo (F)

European Academy of Cancer Sciences, Stockholm, Sweden.
European Cancer Patient Coalition, Brussels, Belgium.

Alexander M M Eggermont (AMM)

European Academy of Cancer Sciences, Stockholm, Sweden.
Department Cancer Medicine, CSO Princess Máxima Centre Pediatric Oncology, University Medical Center Utrecht, The Netherlands.
Board of the Comprehensive Cancer Center Munich, Technical University Munich, Germany.
Ludwig Maximiliaan University, Munich, Germany.

Angel Font (A)

La Caixa Foundation, Barcelona, Spain.

Elena Garralda (E)

Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Cancer Core Europe, Amsterdam, The Netherlands.

Margarida Goulart (M)

Joint Research Center, European Commission, Brussels, Belgium.

Rui Henrique (R)

Department of Pathology & Cancer Biology & Epigenetics Group - Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Centre Raquel Seruca (P.CCC Raquel Seruca), Portugal.
Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Portugal.

Mark Lawler (M)

European Academy of Cancer Sciences, Stockholm, Sweden.
FRCPath Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast, UK.

Lena Maier-Hein (L)

Intelligent Medical Systems (IMSY), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Francoise Meunier (F)

European Academy of Cancer Sciences, Stockholm, Sweden.
Belgian Royal Academy of Medicine, Brussels, Belgium.

Simon Oberst (S)

Quality and Accreditation, Organisation of European Cancer Institutes, Brussels, Belgium.

Pedro Oliveira (P)

Nova School of Business and Economics, Copenhagen Business School & Patient Innovation, Frederiksberg, Denmark.

Maria Papatriantafyllou (M)

Molecular Oncology, FEBS Press, Cambridge, UK.

Joachim Schüz (J)

European Academy of Cancer Sciences, Stockholm, Sweden.
International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Eric Solary (E)

European Academy of Cancer Sciences, Stockholm, Sweden.
INSERM, U1287 and Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France.
Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.

Alfonso Valencia (A)

Barcelona Supercomputing Center (BSC), Barcelona, Spain.
ICREA, Barcelona, Spain.

Rosalia Vargas (R)

Ciencia Viva, Lisbon, Portugal.

Elisabete Weiderpass (E)

European Academy of Cancer Sciences, Stockholm, Sweden.
International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Nils Wilking (N)

Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH